(Authority: Public Law 106–386 Section 107 [22 U.S.C. 7105].)

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2025–13297 Filed 7–15–25; 8:45 am]

BILLING CODE 4184–50–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[OMB #: 0970–0534]

Proposed Information Collection Activity; American Indian and Alaska Natives Facility Condition, Location, and Ownership Survey

AGENCY: Office of Head Start, Administration for Children and Families, U.S. Department of Health and Human Services.

ACTION: Request for Public Comments.

SUMMARY: The Office of Head Start (OHS), Administration for Children and Families (ACF), U.S. Department of Health and Human Services, is proposing to collect data for the American Indian and Alaska Natives (AIAN) Facility Condition, Location, and Ownership Survey. This survey fulfills a statutory requirement and is conducted every 5 years. The previous survey used for this purpose was approved under Office of Management and Budget (OMB) #: 0970–0534; this request will be submitted under the same OMB number.

DATES: Comments due September 15, 2025. In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above.

ADDRESSES: You can obtain copies of the proposed collection of information and submit comments by emailing *infocollection@acf.hhs.gov.* Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: The AIAN Facility Survey is conducted every 5 years in accordance with section 650(b) of the Head Start Act. The most recent survey was approved under OMB #0970–0534 to fulfill the 2020 statutory requirement. This request will be submitted to OMB under the same number as a reinstatement with changes.

The purpose of the survey is to collect current data on the condition, location, and ownership of facilities used by AIAN Head Start programs. The results inform the 2025 Report to Congress and support ongoing policy, funding, and technical assistance decisions. For the 2025 cycle, updates have been made to reflect lessons learned from the 2020 survey and feedback from OHS staff and partners. Changes include more detailed questions on facility safety (*e.g.,* lead testing, pest control, disaster impact), clearer definitions of facility conditions, and expanded items on funding sources and barriers. These revisions aim to strengthen data quality and ensure the survey captures the full scope of infrastructure challenges and needs across AIAN programs.

Respondents: AIAN Early Head Start and Head Start Preschool grantees.

Annual Burden Estimates

Grant recipients will complete the survey for each facility they operate, which based on current grant recipient information is an average of 3.5 responses per respondent. Data collection is expected to take place following OMB approval over a period of about 6 weeks.

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Annual burden hours
AIAN Facility Condition, Location, and Ownership Survey	155	3.5	0.17	92

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

(Authority: 42 U.S.C. 9846.)

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2025–13294 Filed 7–15–25; 8:45 am]

BILLING CODE 4184–40–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–D–5942]

Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled ''Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen; Draft Guidance for Industry.'' The draft guidance document provides blood establishments that collect blood and blood components, including Source Plasma, with FDA's recommendations for testing blood and blood components for hepatitis B surface antigen (HBsAg) to reduce the risk of transfusion-transmitted hepatitis B virus (HBV). The recommendations contained in the guidance apply to the collection of Whole Blood and blood components, including Source Plasma. The draft guidance, when finalized, is intended to supersede the recommendations regarding testing of all blood donations for HBsAg in the guidance document entitled ''Guidance for Industry: Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus'' dated October 2012 (October 2012 Guidance). The guidance, when finalized, will also supersede information on the same topic that is in the document entitled ''Recommendations for the Management of Donors and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg)'' dated December 1987 (December 1987 Memorandum).

DATES: Submit either electronic or written comments on the draft guidance by October 14, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov*. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov*.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2024–D–5942 for ''Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen; Draft Guidance for Industry.'' Received comments will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov*. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf*.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the draft guidance to the Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist the office in processing your requests. The draft guidance may also be obtained by mail by calling CBER at 1–800–835–4709 or 240–402–8010. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Tami Belouin, Center for Biologics Evaluation and Research, Food and Drug Administration, 240–402–7911.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft document entitled ''Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen; Draft Guidance for Industry.'' The draft guidance provides blood establishments that collect blood and blood components, including Source Plasma, with FDA's recommendations for testing blood and blood components for HBsAg to reduce the risk of transfusion-transmitted HBV. The recommendations contained in the guidance apply to the collection of Whole Blood and blood components, including Source Plasma. Specifically, the guidance recommends that when the donations are tested for HBV Deoxyribonucleic acid (DNA) by nucleic acid tests (NAT) and for antibody to hepatitis B core antigen (anti-HBc) using screening tests that FDA has licensed, approved, or cleared for such use, in accordance with the manufacturer's instructions, testing for hepatitis B surface antigen (HBsAg) is not necessary to reduce adequately and appropriately the risk of transmission of HBV. Because Source Plasma donations are not tested for anti-HBc, the draft guidance recommends the continued testing of Source Plasma donations for HBsAg. The draft guidance, when finalized, is intended to supersede the recommendations with respect to blood donations that are tested for HBV NAT and anti-HBc in the October 2012 Guidance and the information on the same topic in the December 1987 Memorandum. Upon finalization of the new recommendations set forth in this draft guidance, we intend to consolidate all FDA recommendations for testing blood and blood components for HBV to issue one guidance that includes finalized recommendations for testing donations to reduce the risk of transfusion transmission of hepatitis B. Except for conforming changes needed to reflect the new recommendations in this draft guidance, we do not intend to revise existing recommendations for HBV donation testing, quarantine and disposition of reactive units, donor deferral and requalification.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ''Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen.'' It does not establish any

rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

As we develop any final guidance on this topic, FDA will consider comments on the applicability of Executive Order 14192, per OMB guidance M–25–20, and in particular, on any costs or cost savings.

II. Paperwork Reduction Act of 1995

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3521). The collections of information in 21 CFR part 601 have been approved under OMB control number 0910–0338 and the collections of information in 21 CFR parts 610 and 630 have been approved under OMB control number 0910–0116.

III. Electronic Access

Persons with access to the internet may obtain the draft guidance at *https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, https://www.fda.gov/regulatory-information/search-fda-guidance-documents,* or *https://www.regulations.gov*.

Dated: July 11, 2025.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025–13272 Filed 7–15–25; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[PO #4820000251; Order #02412–014–004–047181.0]

Notice of Plat of Survey, New Mexico

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of official filing.

SUMMARY: The plat of survey of the following described lands is scheduled to be officially filed 30 days after the date of this notice in the Bureau of Land Management (BLM) NM State Office, Santa Fe, NM. The survey announced in this notice is necessary for the management of lands administered by the U.S. Bureau of Reclamation (BOR).

DATES: If you wish to protest the survey identified in this notice, you must file a written notice of protest with the BLM Chief Cadastral Surveyor for NM by August 15, 2025.

ADDRESSES: Submit written protests to the BLM NM State Office, 301 Dinosaur Trail, Santa Fe, NM 87508. You may obtain a copy of the survey record from the public room at this office upon required payment. The plat may be viewed at this location at no cost.

FOR FURTHER INFORMATION CONTACT: Jacob B. Barowsky, Chief Cadastral Surveyor; (505) 761–8903; *jbarowsky@blm.gov*. Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.

SUPPLEMENTARY INFORMATION: Rio Arriba County, NM:

The plat representing the dependent resurvey and survey of land in the Tierra Amarilla Grant, accepted May 20, 2025, for Group No. 1218, NM.

This plat was prepared at the request of the BOR, Albuquerque Area Office.

A person or party who wishes to protest this survey must file a written notice of protest by the date specified in the **DATES** section of this notice with the NM State Director, BLM, at the address listed in the **ADDRESSES** section of this notice.

A written statement of the reasons in support of the protest, if not filed with the notice of protest, must be filed with the BLM State Director for NM within 30 calendar days after the notice of protest is received.

Before including your address, or other personal information in your protest, please be aware that your entire protest, including your personal identifying information, may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

(Authority: 43 U.S.C. Chap. 3)

Jacob B. Barowsky,

Chief Cadastral Surveyor for NM.

[FR Doc. 2025–13302 Filed 7–15–25; 8:45 am]

BILLING CODE 4331–23–P

DEPARTMENT OF THE INTERIOR

Bureau of Ocean Energy Management

[Docket No. BOEM–2025–0035]

Commercial Leasing for Outer Continental Shelf Minerals Offshore American Samoa—Request for Information and Interest; Extension of Comment Period

AGENCY: Bureau of Ocean Energy Management, Interior.

ACTION: Request for information and interest; extension of the comment period.

SUMMARY: The Bureau of Ocean Energy Management (BOEM) announces a 30-day extension of the comment period for the request for information and interest (RFI) for leasing of the Outer Continental Shelf minerals in and around an area offshore American Samoa, referred to as the RFI Area.

DATES: BOEM published the RFI on June 16, 2025, and opened a public comment period through July 16, 2025. BOEM is extending this public comment period to August 15, 2025. BOEM must receive all comments, information, and indications of interest in response to this RFI no later than August 15, 2025.

ADDRESSES: Please submit indications of interest in commercial leasing electronically via email to *Pacific.Region@boem.gov* or by hard copy by mail to the following address: Bureau of Ocean Energy Management, Pacific Region, Office of Strategic Resources, 760 Paseo Camarillo (CM 102), Camarillo, California 93010. If you elect to mail a hard copy, also include an electronic copy on a portable storage device. Do not submit indications of interest via the Federal eRulemaking Portal.

Please submit all other comments and information as discussed in section 6 of the June 16, 2025, RFI entitled, ''Types of Information and Comments Requested,'' by either of the following two methods:

1. *Federal eRulemaking Portal: http://www.regulations.gov*. In the search box at the top of the web page, enter BOEM–2025–0035 and then click ''search.'' Follow the instructions to submit public comments and to view supporting and related materials.

2. *By mail to the following address:* Bureau of Ocean Energy Management, Pacific Region, Office of Strategic Resources, 760 Paseo Camarillo (CM 102), Camarillo, California 93010.

Treatment of confidential information is addressed in section 8 of the June 16, 2025, RFI entitled, ''Protection of